X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

ICYMI: New era of medicine initiative kicks off in Boston

By Andrew Powaleny  |    February 22, 2017
It’s no secret that Boston, Massachusetts is home to many of the most groundbreaking advancements in medical discovery. That’s why yesterday, PhRMA sponsored its first national health care...   Read More

Biopharmaceutical industry’s success reducing disparities for African Americans

By Myisha Gatson  |    February 16, 2017
February is Black History Month, and here at PhRMA, we continue our decades-long commitment to reducing disparities in health care for minorities through developing and helping communities access...   Read More

10 years of living and managing type 1 diabetes; lessons learned

By Guest Contributor  |    November 30, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

By Hannah Mooney  |    November 14, 2016
Today, there are more than 30 million Americans suffering from type 1 or type 2 diabetes. Roughly 5 percent of patients have type 1 and 90 to 95 percent suffer from type 2, highlighting the...   Read More

New PhRMA report: New medicines in development for autoimmune diseases offer patients hope for brighter futures

By Hannah Mooney  |    September 12, 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and...   Read More

Patients showcase longer, healthier lives in new “From Hope to Cures” ads

By Ieva M. Augstums  |    September 6, 2016
For Ed, a longer life meant more time with family, friends and his dog, BearBear. When he was diagnosed with colon cancer, he underwent six weeks of radiation, seven months of chemotherapy and 10...   Read More

Medicare Monday: Concerns still abound about Part B proposal

By Allyson Funk  |    August 15, 2016
We’ve covered many of the concerns about the government’s overreaching proposal to change Medicare Part B payments and negatively impact seniors’ access to treatment. A lack of patient protections...   Read More

Celebrating diversity in the biopharmaceutical industry

By Andrew Powaleny  |    June 30, 2016
At PhRMA, we often talk about the complexity of developing innovative medicines. Critical to researching new medicines is a workforce that combines sheer brainpower with a level of perseverance...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates